Tocqueville Asset Management L.P. Acquires 8,950 Shares of GSK plc (NYSE:GSK)

Tocqueville Asset Management L.P. boosted its holdings in GSK plc (NYSE:GSK) by 23.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 46,900 shares of the pharmaceutical company’s stock after purchasing an additional 8,950 shares during the period. Tocqueville Asset Management L.P.’s holdings in GSK were worth $1,586,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in GSK. Indiana Trust & Investment Management Co lifted its stake in shares of GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after acquiring an additional 500 shares during the last quarter. Crews Bank & Trust purchased a new position in GSK in the 4th quarter worth approximately $26,000. ST Germain D J Co. Inc. lifted its position in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. Sunbelt Securities Inc. boosted its stake in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Finally, Sierra Ocean LLC bought a new position in shares of GSK in the fourth quarter worth approximately $32,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Down 2.1 %

NYSE:GSK opened at $39.53 on Thursday. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93. The company has a market capitalization of $81.81 billion, a PE ratio of 24.86, a P/E/G ratio of 1.12 and a beta of 0.58. The firm’s 50-day moving average price is $36.42 and its 200-day moving average price is $36.98. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, equities analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a yield of 3.98%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio is 98.74%.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of recent analyst reports. Morgan Stanley started coverage on shares of GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, GSK has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.